Replies to post #9819 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

I see no reason that approvals will come before or at patent expiration, 2015.

I also see no reason at this point that Mylan isn't in the game along with Momenta. I'm also confused as to what Synthon BV has up its sleeve regarding their GTR comparison study.

Copaxone's 'generic' position doesn't seem as positive as once thought.